NEW YORK (GenomeWeb News) – Decode Genetics said today that it has licensed three genetic markers for cardiovascular and metabolic diseases to Celera.

The markers may be used to create lab tests for individual risks of heart attack, stroke, atrial fibrillation, and type 2 diabetes, Decode said.

Under the agreement, Decode will receive an upfront payment and royalties from sales of testing products that use the markers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.